Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pre-hospital zalunfiban for STEMI
NL-OMON56301Phase 3Recruiting
- Sponsor
- CeleCor Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zalunfiban in myocardial infarction (MI) (3 arms), sponsored by CeleCor Therapeutics. Primary endpoints: 30-day hierarchical 7-point clinical outcome, Severe or life-threatening bleeding and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
zalunfiban
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON56301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56301.